Kodiak Sciences Inc. (KOD): Total Liabilities
$194.15M
As of 2025-12-31
$195.72M
As of 2026-06-30
-5.6%
3-year compound annual growth
-1.2%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $194.15M | +4.8% | 2026-03-31, Balance as of period end |
| 2024-12-31 | $185.29M | -13.3% | 2026-03-31, Balance as of period end |
| 2023-12-31 | $213.59M | -7.3% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $230.46M | -4.3% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $240.90M | +16.6% | 2023-03-28, Balance as of period end |
| 2020-12-31 | $206.60M | n/m | 2022-03-01, Balance as of period end |
| 2019-12-31 | $13.51M | +152.2% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $5.36M | -75.6% | 2020-03-16, Balance as of period end |
| 2017-12-31 | $21.96M | n/a | 2019-03-27, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Kodiak Sciences Inc. (KOD) | 2025-12-31 | $194.15M | +4.8% |
| C4 Therapeutics, Inc. (CCCC) | 2025-12-31 | $102.49M | -23.3% |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | $96.38M | +8.5% |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | $221.87M | +53.7% |
| Scilex Holding Co (SCLX) | 2025-12-31 | $576.73M | +101.9% |
| Prokidney Corp. (PROK) | 2025-12-31 | $34.78M | -11.8% |
| Replimune Group, Inc. (REPL) | 2026-03-31 | $166.23M | +22.7% |
| Maze Therapeutics, Inc. (MAZE) | 2025-12-31 | $42.16M | -3.4% |
| LENZ Therapeutics, Inc. (LENZ) | 2025-12-31 | $21.54M | +92.0% |
Compare KOD, CCCC, TSHA, PRME side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗